Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
P18-BE3CRC
- Development stage
- Preclinical
- Lead developer
- iNtRON Biotechnology
- Modality
- Adenine Base Editors → Base Editing → Gene Editing → Gene Therapies, Peptides, Recombinant Proteins and Enzymes, Cytosine Base Editors → Base Editing → Gene Editing → Gene Therapies
- Administration
- Intravenous
01
Overview
P18-BE3CRC is an experimental base editing therapeutic system designed for the targeted treatment of colorectal cancer (CRC). The construct utilizes the **BE3** (Base Editor 3) system, a first-generation cytidine base editor composed of a rat APOBEC1 deaminase fused to a Cas9 nickase (nCas9) and a uracil glycosylase inhibitor (UGI). Selective delivery to tumor cells is achieved via the **P18** tumor-homing peptide (sequence: YHWYGYTPQNVI), which specifically binds to **GRP78** (HSPA5), a molecular chaperone overexpressed on the surface of colorectal cancer cells. Once internalized, the BE3 system performs precise cytosine-to-thymine (C-to-T) conversions at target genomic loci. A primary therapeutic application of P18-BE3CRC is the disruption of the **CTNNB1** (beta-catenin) oncogene, where it can introduce premature stop codons to silence overactive Wnt signaling, thereby inhibiting tumor growth and progression. This approach represents a non-viral, peptide-mediated delivery strategy for CRISPR-based base editing in oncology.
- Other names
- P18-BE3P-18-BE3P 18-BE3P18-mediated BE3P-18-mediated BE3P 18-mediated BE3
02
Targets
CTNNB1 (Beta-catenin)
Beyond the preview
Go deeper on P18-BE3CRC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on P18-BE3CRC.